AUA 2024: Dr. Smelser recaps key bladder cancer research
Woodson W. Smelser, MD, discusses key bladder cancer data that was presented at the 2024 AUA Annual Meeting.
In this interview, Woodson W. Smelser, MD, discusses key bladder cancer data that was presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Smelser is an assistant professor of surgery at Washington University School of Medicine in St. Louis, Missouri.
During the discussion, Smelser highlights the following abstracts:
1. P2-01: TAR-200 in patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer: Results from SunRISe-1 study
2. P2-02: Pivotal results from BOND-003: A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
3. P2-08: LEGEND: a phase 1/2 study of EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS)
4. PD48-01: Efficacy of Nadofaragene Firadenovec-vncg for Patients With BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Final Results From a Phase 3 Trial
5. PD34-10: First results of NURE-Combo: a phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC)
Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer
February 7th 2022To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.
How appropriate use criteria for PSMA-PET imaging optimize patient care
February 2nd 2022In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.
Dr. Padmanabhan discusses impact of COVID-19
June 11th 2020Urology Times® Editorial Council Member Priya Padmanabhan, MD, MPH, professor of urology at Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, discusses how she has been affected by the coronavirus disease 2019 (COVID-19) pandemic.
